MwanzoATHA • NASDAQ
add
Athira Pharma Inc
$ 0.28
Baada ya Saa za Kazi:(0.00%)0.00
$ 0.28
Imefungwa: 25 Apr, 20:00:00 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 0.30
Bei za siku
$ 0.28 - $ 0.31
Bei za mwaka
$ 0.22 - $ 3.67
Thamani ya kampuni katika soko
11.25M USD
Wastani wa hisa zilizouzwa
elfu 237.93
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 15.57M | -49.20% |
Mapato halisi | -15.00M | 45.01% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | — | — |
EBITDA | -15.32M | 49.59% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 51.28M | -65.22% |
Jumla ya mali | 58.78M | -63.32% |
Jumla ya dhima | 13.94M | -53.63% |
Jumla ya hisa | 44.84M | — |
hisa zilizosalia | 39.04M | — |
Uwiano wa bei na thamani | 0.26 | — |
Faida inayotokana na mali | -53.67% | — |
Faida inayotokana mtaji | -74.16% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -15.00M | 45.01% |
Pesa kutokana na shughuli | -26.01M | 1.06% |
Pesa kutokana na uwekezaji | -2.81M | -144.00% |
Pesa kutokana na ufadhili | elfu 34.00 | -77.63% |
Mabadiliko halisi ya pesa taslimu | -28.79M | -45.78% |
Mtiririko huru wa pesa | -12.30M | 32.48% |
Kuhusu
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Ilianzishwa
2011
Makao Makuu
Tovuti
Wafanyakazi
26
